Following the Council’s adoption of the so-called Pharma Package (consisting of a new Regulation and a new Directive) at the end of September 2026, the legislative process is approaching its final stage. The texts are now awaiting formal adoption by the European Parliament before entering into force 20 days after their publication in the Official Journal of the European Union, likely by the end of 2026. The new Regulation will become applicable 2 years after entry into force, while Member States will be required to transpose the new Directive into national law within the same timeframe.
In this article, we compare the most relevant changes regarding regulatory exclusivity periods, orphan medicinal products, and the revised “Bolar” exemption under the Pharma Package with the current legal framework.
1. Changes to regulatory exclusivity periods
| Current regime: 8 +2(+1) | Pharma Package: 8(+1) +1(+1)(+1) | |
| Baseline regulatory data protection (RDP) | 8 years. | 8 years. |
| RDP for repurposed medicinal products | 1 year (non-cumulative) for a new indication for a well-established substance (used within the EU for at least 10 years with recognised efficacy and acceptable safety level), in case significant pre-clinical or clinical studies regarding the new indication were carried out. |
4 years for a new indication not previously authorised in the EU for a “re-purposed” medicinal product (based on an already known active substance) subject to the following requirements:
This 4-year RDP period can only be granted once per medicinal product. |
| Extension of RDP | N/A | +1 year, in case an exclusivity voucher, which was granted for the development of a "priority antimicrobial”, is used. |
| Baseline regulatory market protection (RMP) | 2 years. | 1 year. |
| Extension of RMP | +1 year for a new indication bringing a significant clinical benefit. |
Up to +2 years possible:
|
| Transitional provisions | The new regulatory data and market protection periods will only apply to MA applications submitted after the new Regulation and Directive become applicable in 2028. For applications submitted before that date, the current regulatory exclusivity periods will continue to apply. | |
2. Changes regarding orphan medicinal products
| Current regime | Pharma Package | |
| Orphan designation | Decisions on the orphan status of a medicinal product are taken by the European Commission based on an opinion of the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA). | EMA itself will grant orphan designations within 90 days of receipt of a valid application. |
| Orphan designations are valid without limitation. | Orphan designations are valid for 7 years, which can be extended in the case of ongoing, promising clinical studies. | |
| Baseline orphan market exclusivity (OME) | 10 years. | 11 years for breakthrough orphan medicinal products, i.e., orphan medicinal products for an indication, for which no authorised product exists, and which bring a clinically relevant reduction in disease morbidity or mortality; 4 years for orphan medicinal products authorised based on bibliographical data; and 9 years for all other orphan medicinal products. |
| Extension of OME | OME is granted on an indication specific basis – an MA for a new orphan indication leads to a separate full OME for this indication. | The concept of a global orphan MA is introduced. |
| Indication stacking by obtaining separate orphan MAs with separate OME periods is possible, potentially extending the overall OME for one orphan medicinal product far beyond 10 years. | No more indication stacking – later orphan MAs for other indications of the same medicinal product do not trigger new OME periods. | |
| +2 years per orphan indication, if the results of studies conducted in accordance with an agreed paediatric investigation plan (PIP) are reflected in the MA application or in the summary of product characteristics (SmPC). | +1 year of global OME if the orphan MA holder obtains an MA for one or more new indications for a different orphan condition at least 2 years before the end of the OME period – this can be granted twice for two different orphan conditions, resulting in a maximum cumulative extension of 2 years. This extension does not apply to orphan medicinal products authorised based on bibliographical data. No paediatric OME extension. |
|
| Reduction of OME | Review of eligibility criteria for OME 6 years after the MA is granted. | N/A |
| Effects of OME | During the OME period, MA applications may not be accepted, and MAs/MA extensions may not be granted for similar medicinal products in the same therapeutic indication – effectively further extending the OME period. | The submission, validation and assessment of MA applications for similar medicinal products will be possible during the last two years before the OME expires – accordingly, generic or biosimilar products could be placed on the market immediately upon expiry of the OME. |
| Paediatric supplementary protection certificate (SPC) extension | Orphan medicinal products can be granted a +2-year OME extension if the results of studies conducted in accordance with an agreed PIP are reflected in the MA application or in the SmPC (see above) but are not able to benefit from a 6-month paediatric SPC extension for the completion of an agreed PIP. | The 6-month paediatric SPC extension also applies to orphan medicinal products if the results of studies conducted in accordance with an agreed PIP are reflected in the MA application or in the SmPC. |
| Transitional provisions |
Validity of orphan designations: For orphan designations granted before the new Regulation becomes applicable, the 7-year validity period will begin to run from the date of application of the new Regulation. OME periods:
|
|
3. Changes to the “Bolar” exemption
| Current regime | Pharma Package | |
| Legal basis |
Article 10(6) of Directive 2001/83/EC: Conducting the necessary studies and trials with a view to the application of paragraphs 1, 2, 3 and 4 and the consequential practical requirements shall not be regarded as contrary to patent rights or to supplementary protection certificates for medicinal products. |
Article 87 of the new Directive:
(a) obtaining marketing authorisations, in particular for generic, biosimilar, hybrid or bio-hybrid medicinal products and for subsequent variations; (b) conducting health technology assessments (…); (c) obtaining pricing and reimbursement approvals; (d) complying with subsequent practical requirements associated with activities referred to in points (a), (b) and (c); (e) submitting an application on procurement tenders, in compliance with Union and national law, to the extent that it does not entail the sale or offering for sale or marketing of the medicinal product concerned during the protection period provided by patent rights or supplementary protection certificates. The activities conducted exclusively for the purposes set out in the first subparagraph may cover, where relevant, the submission of a marketing authorisation application and the offer, manufacture, sale, supply, storage, import, use and purchase of medicinal products or processes, including by third party suppliers and service providers. |
| Implications | The current “Bolar” exemption was transposed inconsistently into national law across the EU. Some Member States followed a restrictive approach, while others interpreted the “Bolar” exemption more broadly in terms of its material, personal, and territorial scope. This divergent implementation led to a high level of legal uncertainty. | The Pharma package aims to harmonise the application of the “Bolar” exemption and clarify its scope. In doing so, it generally follows a rather broad approach, potentially enabling earlier generic/ biosimilar market entry and resulting in revenue losses for originators. Since the “Bolar” provision is included in the new Directive, it will again have to be transposed into the national law of the Member States. |
| Transitional provisions | Since there is no explicit transitional provision for the new “Bolar” exemption, it will apply 24 months after the Directive enters into force, by which time the Member States must have transposed it into national law. | |
For a concise overview of the key changes to regulatory and orphan exclusivities under the EU Pharma Package, read our summary.